May 12, 2023 / NTS GMT
Brent Barnes - LBT Innovations Limited - CEO, Managing Director
Look, I want to start with our mission. We are disrupting microbiology culture plate reading. It's really simple. It's really specific. And that's because the microbiology market is huge and it's really ripe for disruption.
So if we go to first slide after the disclaimer, I really wanted to wrap up the investment highlights in one slide just to get your attention if you like. We are a commercial-stage company. We are generating revenue. Our technology, back to our mission, automates culture plate reading in microbiology.
It's a validated hardware platform as well as an AI capability. Importantly, it's a single platform and architecture and we're focused at the moment on two really major markets, it's clinical microbiology and pharmaceutical quality control microbiology.
And when you look at each of those markets, we have really big companies that are backing that technology. Thermo Fisher are our exclusive distributors for APAS in the clinical market. AstraZeneca is funding as well as partnering with us for the pharma
LBT Innovations Ltd at Sharecafe Hidden Gems Webinar Transcript
May 12, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers